Prepared By R.R. Donnelley Financial -- Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C., 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date Of Report (Date Of Earliest Event Reported): 10/05/2005

OXIS International, Inc.

(Exact Name of Registrant as Specified in its Charter)

Commission File Number: 000-08092

DE		94-1620407
(State or Other Jurisdiction of		(I.R.S. Employer
Incorporation or Organization)		Identification No.)

6040 N Cutter Circle Suite 317, Portland, OR 97217

(Address of Principal Executive Offices, Including Zip Code)

503-283-3911

(Registrant’s Telephone Number, Including Area Code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))

Items to be Included in this Report

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

(d) Election of Directors

On October 5, 2005 the board of directors of OXIS International, Inc. appointed John E. Repine, M.D. as a member of the board of directors, effective immediately, to serve until the next annual meeting of stockholders. On October 7, 2005, OXIS International issued a press release announcing the appointment of Dr. Repine to the board of directors. A copy of the press release is attached as Exhibit 99.1 under Item 9.01 of this Report.

Item 9.01. Financial Statements and Exhibits

99.1 Press Release dated October 7, 2005 entitled "Dr. John Repine, M.D., CEO and Scientific Director of the Webb-Waring Institute for Cancer, Aging and Antioxidant Research Joins OXIS' Board of Directors."

Signature(s)

Pursuant to the Requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned hereunto duly authorized.

		OXIS International, Inc.


Date: October 07, 2005.	By:	/s/ Steven T. Guillen
		Steven T. Guillen
		President & CEO

Exhibit Index

Exhibit No.		Description
EX-99.1		Press Release, dated October 7, 2005

EX-99.1 2 rrd94341_8725.htm PRESS RELEASE, DATED OCTOBER 7, 2005 Former Vice President Al Gore Joins Apple's Board of Directors

EXHIBIT 99.1

Media Relations
Anna Gralinska
Deliberate Co.
Tel: (877)879-2994
annag@deliberatecompany.com

Dr. John Repine, M.D., CEO and Scientific Director of the Webb-Waring Institute for Cancer, Aging and Antioxidant Research Joins OXIS' Board of Directors

PORTLAND, Ore. -- October 7, 2005 -- OXIS International, Inc. (OTCBB: OXIS.OB) (Nouveau Marché: OXIS) (FWB: OXI), specialists in developing technologies for the diagnosis of diseases resulting from oxidative stress, announced today that Dr. John Repine, M.D., CEO, President and Scientific Director of the Webb-Waring Institute for Cancer, Aging and Antioxidant Research, and a respected authority in the study of lung and vascular diseases has joined OXIS' Board of Directors.

"John brings a wealth of industry and scientific research knowledge to OXIS," said Steve Guillen, CEO and President of OXIS. "We are excited and honored that he has agreed to serve on our board and look forward to his contribution."

"Steve and his team have done a great job in refocusing OXIS on the path to growth and profitability," said Dr. John Repine. "I look forward to working with the other board members to continue to help advance the company's stated goals."

In addition to having led the Webb-Waring Institute since 1993, Dr. Repine is the James J. Waring Professor in the Department of Medicine and Pediatrics at the University of Colorado Health Sciences Center. Under his leadership, the Webb-Waring Institute's research program has brought together a team of scientists who collaborate on the investigation of the causes and prevention of many diseases, including cancer, through a multi-disciplinary study of antioxidants and inflammation. His work is supported by National Institutes of Health (NIH) and Foundation grants.

The author of more than 300 original peer-reviewed research and review articles, Dr. Repine is also a reviewer and on the editorial boards of numerous prominent professional journals. He is a member of several professional and honorary medical societies and is the recipient of the Bonfils-Stanton Award for outstanding contributions to medicine and science, among others.

Dr. Repine is also recognized as a distinguished teacher. He has won numerous awards including the Distinguished Faculty Scholar Award, the Dean Joseph W. St. Geme Award for Outstanding Contributions to the School of Medicine and the prestigious University of Colorado Presidential Teaching Award for 1995.

About OXIS

OXIS International Inc., headquartered in Portland, Oregon, focuses on developing technologies and products to research, diagnose, treat and prevent diseases associated with damage from free radical and reactive oxygen species -- diseases of oxidative stress. The company holds the rights to three therapeutic classes of compounds in the area of oxidative stress, and develops, manufactures and markets products and technologies to diagnose and treat diseases caused by oxidative stress. More information about OXIS and its products, services as well as current SEC filings may be obtained by visiting the Company's Web site at http://www.oxis.com.

# # #

-----END PRIVACY-ENHANCED MESSAGE-----